Even though minimally invasive surgery has improved outcomes for hysterectomy, the procedure requires removal of the uterus through small incisions. Morcellation, or fragmentation of the uterus into smaller pieces, is one method to remove the uterus. Recently, concern has been raised that morcellation may result in the spread of undetected malignancies. 1 Despite the commercial availability of electric power morcellators for 2 decades, accurate estimates of the prevalence of malignancy at the time of electric power morcellation (herein referred to as morcellation) are lacking, 1,2 with single-center studies reporting prevalences from 9 to 100 in 10 000. 3, 4 We used a large insurance database to investigate the prevalence of underlying cancer in women who underwent uterine morcellation.
Even though minimally invasive surgery has improved outcomes for hysterectomy, the procedure requires removal of the uterus through small incisions. Morcellation, or fragmentation of the uterus into smaller pieces, is one method to remove the uterus. Recently, concern has been raised that morcellation may result in the spread of undetected malignancies. 1 Despite the commercial availability of electric power morcellators for 2 decades, accurate estimates of the prevalence of malignancy at the time of electric power morcellation (herein referred to as morcellation) are lacking, 1,2 with single-center studies reporting prevalences from 9 to 100 in 10 000. 3, 4 We used a large insurance database to investigate the prevalence of underlying cancer in women who underwent uterine morcellation.
Methods | The Perspective database was used to identify women who underwent a minimally invasive hysterectomy from 2006-2012. Perspective is an all-payer database including more than 500 hospitals capturing 15% of hospitalizations. Hospitals within this database are more frequently urban teaching centers and located in the southern United States. Data undergo a rigorous quality control process. Use of commercially available morcellators was captured by identification of charge codes. 5 The analysis was deemed exempt by the Columbia University institutional review board.
The primary outcome was identification of uterine corpus cancer (all histologies) based on International Classification of Diseases, Ninth Revision, coding at surgery. We also examined the occurrence of uterine neoplasms of uncertain malignant potential; malignancies of other parts of the uterus, including cervical cancer, and surrounding adnexal structures (other gynecologic cancer); and endometrial hyperplasia.
Multivariable mixed-effects log-linear models, including clinical and demographic covariates and a random-intercept for the procedural hospital, were developed for uterine cancer and endometrial hyperplasia. The other outcomes were rare and the models did not converge.
All statistical analyses were 2-sided and performed with SAS version 9.4 (SAS Institute Inc). A P value of <.05 was considered statistically significant.
Results | Within the cohort of 232 882 women who underwent minimally invasive hysterectomy from 2006-2012, morcellation was performed in 36 470 (15.7%). Women who underwent morcellation differed in clinical and demographic characteristics from women who did not (eTable in the Supplement). Among those who underwent morcellation, 99 cases of uterine cancer were identified, a prevalence of 27/10 000 (95% CI, 22-32/10 000). Twenty-six cases of other gynecologic malignancies were found (a prevalence of 7/10 000 [95% CI, 4-10/10 000]), 39 uterine neoplasms of uncertain malignant potential (11/10 000 [95% CI, 7-14/ 10 000]), and 368 cases of endometrial hyperplasia (101/ 10 000 [95% CI, 91-111 per 10 000]).
Among women who underwent morcellation, advanced age was associated with underlying cancer and endometrial hyperplasia (Table) . Compared with women younger than 40 years, the prevalence ratio for a uterine malignancy increased with increasing age from 4.97 (95% CI, 1.91-12.93) in women aged 50 to 54 years, to 19.37 (95% CI, 7.66-48.95) in those aged 55 to 59 years, to 21.36 (95% CI, 7.22-63.21) in those aged 60 to 64 years, and to 35.97 (95% CI, 14.14-91.53) for women aged 65 years or older.
Discussion | Our data demonstrate that uterine cancers occurred in 27 per 10 000 women undergoing morcellation. Other malignancies and precancerous abnormalities were also detected. Although morcellators have been in use since 1993, few studies have described the prevalence of unexpected pathology at the time of hysterectomy. [2] [3] [4] Prevalence information is the first step in determining the risk of spreading cancer with morcellation. Although data are limited, women with apparent uterine-confined neoplasms at the time of morcellation have been found to have intraperitoneal tumor dissemination at the time of reexploration. 3, 6 We recognize a number of limitations including the inability to verify pathological findings, possible misclassification of pathology, potential undercapture of morcellation, and the fact that our findings may not be generalizable to all hospitals. Last, we lack data on long-term follow-up, and the outcome of women with pathological abnormalities who underwent morcellation requires further study. Patients considering morcellation should be adequately counseled about the prevalence of cancerous and precancerous conditions prior to undergoing the procedure. 
COMMENT & RESPONSE

PET Screening for Metastatic Colorectal Adenocarcinoma
To the Editor Dr Moulton and colleagues 1 concluded that positron emission tomography (PET) combined with computed tomography (CT) compared with diagnostic CT alone did not significantly change the management of patients with potentially resectable metastatic colorectal adenocarcinoma. However, we are concerned about some issues related to the use of PET-CT.
The study used PET-CT primarily for restaging because more than 70% of the patients received adjuvant chemotherapy prior to presurgical staging. 1 However, comparison with an initial staging PET is important when deciding on therapy and assessing treatment response. Moulton et al 1 described how their results differed from other studies, 2,3 but those studies performed baseline PET imaging before any adjuvant therapy.
The study excluded a large number of patients with suspected extrahepatic disease (essentially all of those who failed adjuvant therapy). These patients could have benefited from PET-CT, leading to selection bias. Studies that demonstrated a benefit from preoperative staging with PET scans did so prior to initiating therapy. 2 The PET acquisition protocol used a 60-minute uptake time, which has been proven to be inadequate when evaluating hepatic colorectal metastases due to a decreased target to background ratio, unless using a systematic method of analysis. 4 The cases with false-positive results reported in the supplementary material may not be true false-positives. Areas of known physiological or incidental activity can be amplified if variations in uptake time, patient rest during uptake, fasting insulin status, glucose levels, and reconstruction are not minimized. Many PET readers would classify these as spurious or incidental findings that are not likely to affect the management of colorectal carcinoma.
There is reader-order bias in the comparison of PET with prior CT scans. First, CT scans were assessed prior to randomization and repeated if not technically acceptable, thus ensuring limited patient artifacts, adequate boluses of intravenous contrast, and accurate vascular phase imaging. It was not stated how many CT scans were repeated during the study. Second, the PET interpreter had the CT available for comparison and could retrospectively identify lesions on CT with the benefit of those lesions seen on the PET scan.
It would have been more appropriate to use the original CT interpretation and blind the PET readers to its results to assess the true additional value of PET scan. The study did not address the reverse situation: how many lesions were seen on the CT portion of PET-CT that were present on the dedicated CT (ie, what is the advantage of dedicated contrast CT compared with PET-CT)?
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